

10/533070

JC12 Rec'd PCT/PTO 28 APR 2005

Express Mail No. EV514612545US

Date of Deposit: April 28, 2005

PATENT

WDN/SLR:dm 04/26/05 899-67103-02 378901 610

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dennis R. Trune

Application No. Currently unknown

Filed: Herewith

Confirmation No. Currently unknown

For: FLUDROCORTISONE TREATMENT FOR
HEARING LOSS

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 899-67103-02

MAIL STOP PCT

COMMISSIONER FOR PATENTS

P.O. BOX 1450

ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(1)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Copies of United States patents and United States published patent applications do not have to be provided to the Patent Office (37 C.F.R. 1.98(a)(2)(ii)). Copies of unpublished U.S. applications do not have to be provided, as long as the application is available on PAIR, as this requirement of 37 C.F.R. § 1.98(a)(2)(iii) has been waived by the United States Patent and Trademark Office pursuant to the Official Gazette Notice on October 19, 2004 (1287 OG 163). Applicant will provide copies of such patents or applications upon request.

JC12 PCT/PTC 10/533070
28 APR 2005

Express Mail No. EV514612545US
Date of Deposit: April 28, 2005
PATENT


WDN/SLR:dm 04/26/05 899-67103-02 378901 610

Applicant filed this Information Disclosure Statement ("IDS") within three months of the filing date of a national application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicant to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	899-67103-02
	Application Number	Currently unknown 10/533070
	Filing Date	April 28, 2005
	First Named Inventor	Trune
	Art Unit	Not yet assigned
	Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee
		2003/0040509 A1	2/27/2003	Moskowitz

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Gross et al., "Spironolactone Blockade of Steroid-Mediated Hearing Improvement in Autoimmune Mice," <i>Otolaryngol. Head & Neck Surgery</i> 125(2):P87, 2001.
		Gross et al., "Spironolactone Blocks Glucocorticoid-Mediated Hearing Preservation in Autoimmune Mice," <i>Laryngoscope</i> 112:298-303 (2002).
		Kaylie et al., "Steroid Treatments Restore Stria Vascularis Capillary Size in MRL/MpJ-Fas ^{lpr} Autoimmune Mice," Abstracts of the Twenty-Fifth Annual Midwinter Research Meeting, St. Petersburg Beach, Florida, January 27-31, 2002, <i>Assoc. Res. Otolaryngol.</i> 25:169 (Abstract #644).
		Lindman, "Hope on the Horizon for Hearing Impairment," <i>Oregon Health Magazine</i> 3:22-25 (2001).
		Mateijssen et al., "Aldosterone Assessment in Patients with Menière's Disease," <i>ORL J. Otorhinolaryngol. Relat. Spec.</i> 63:280-286 (2001).
		Trune et al., "Aldosterone (Mineralocorticoid) Equivalent to Prednisolone (Glucocorticoid) in Reversing Hearing Loss in MRL/MpJ-Fas ^{lpr} Autoimmune Mice," <i>Laryngoscope</i> 110:1902-1906 (2000).
		Trune et al., "Aldosterone and Prednisolone Control of Cochlear Function in MRL/MpJ-Fas ^{lpr} Autoimmune Mice," <i>Hearing Res.</i> 155:9-20 (2001).
		Trune et al., "Proposed Mechanisms of Steroid Responsive Hearing Loss," Abstracts of the Twenty-Fifth Annual Midwinter Research Meeting, St. Petersburg Beach, Florida, January 27-31, 2002, <i>Assoc. Res. Otolaryngol.</i> 23:89 (Abstract #338).

EXAMINER SIGNATURE:	DATE CONSIDERED:
------------------------	---------------------

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	899-67103-02
Application Number	Current unknown
Filing Date	April 28, 2005
First Named Inventor	Trune
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

[illegible]

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.